Zykadia 150 mg hard capsules

  • Name:

    Zykadia 150 mg hard capsules

  • Company:
    info
  • Active Ingredients:

    Ceritinib

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 10/04/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 10/4/2019
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Click on this link to Download PDF directly

Novartis Ireland Limited

Novartis Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Exelon capsules Active Ingredients Rivastigmine hydrogen tartrate
Medicine Name Exelon Transdermal Patches Active Ingredients Rivastigmine
Medicine Name Exforge film-coated tablets Active Ingredients Amlodipine besylate, Valsartan
Medicine Name Exforge HCT film-coated tablets Active Ingredients Amlodipine besylate, Hydrochlorothiazide, Valsartan
Medicine Name Exjade Film-Coated Tablets Active Ingredients Deferasirox
Medicine Name Femara 2.5 mg Film Coated Tablet Active Ingredients Letrozole
Medicine Name Foradil Active Ingredients Formoterol fumarate dihydrate
Medicine Name Galvus 50mg tablets Active Ingredients Vildagliptin
Medicine Name Gilenya Capsules Active Ingredients fingolimod hydrochloride
Medicine Name Glivec 100 mg film-coated tablets Active Ingredients Imatinib mesilate
Medicine Name Glivec 400 mg film-coated tablets Active Ingredients Imatinib mesilate
Medicine Name HYCAMTIN 0.25 mg and 1 mg hard capsules Active Ingredients Topotecan Hydrochloride
Medicine Name HYCAMTIN 1mg and 4mg solution Active Ingredients Topotecan Hydrochloride
Medicine Name Iopidine 1% Eye Drops Solution Active Ingredients Apraclonidine Hydrochloride
Medicine Name Iopidine 5mg/ml Eye Drops Solution Active Ingredients Apraclonidine Hydrochloride
Medicine Name Jakavi Tablets Active Ingredients Ruxolitinib Phosphate
Medicine Name Kisqali 200 mg film-coated tablets Active Ingredients Ribociclib succinate
Medicine Name Lamisil 250mg tablets Active Ingredients Terbinafine hydrochloride
Medicine Name Lescol XL 80mg prolonged release tablets Active Ingredients Fluvastatin sodium
Medicine Name Lioresal 5mg/5ml Oral Solution Active Ingredients Baclofen
Medicine Name Lioresal Tablets 10mg Active Ingredients Baclofen
Medicine Name Lucentis 10mg/ml solution for injection in pre-filled syringe Active Ingredients Ranibizumab
Medicine Name Maxidex Eye Drops Active Ingredients Dexamethasone
Medicine Name Maxitrol Eye Drops Active Ingredients Dexamethasone, Neomycin sulfate, Polymyxin B sulfate
Medicine Name Mekinist 0.5mg and 2mg film-coated tablets Active Ingredients Trametinib dimethyl sulfoxide
26 - 50 of 116 items.Total: 5 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 10 April 2019 PIL

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 6 - what the product contains

Updated on 10 April 2019 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Minor editorial changes to Sections 4.2, 6.1 and 6.5.

Updated on 21 March 2019 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink

Updated on 21 March 2019 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Revision of recommendations for concomitant use of Zykadia with CYP3A and CYP2C9 substrates based on A2103 drug interaction study results.

Changes to the list of examples of CYP3A substrates with narrow therapeutic index (NTI) {addition of alfuzosin, amiodarone, dihydroergotamine, quetiapine, lovastatin, simvastatin, sildenafil, midazolam, triazolam and deletion of astemizole}

Updated on 4 September 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 26 July 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 3 July 2018

Updated on 23 May 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 16 September 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 16 September 2015 PIL

Reasons for updating

  • Change to side-effects

Updated on 3 September 2015 PIL

Reasons for updating

  • Introduction of new pack/pack size

Updated on 10 June 2015 PIL

Reasons for updating

  • New PIL for new product